A Phase II, 2-stage Trial of CRLX101 in Combination With Bevacizumab in Recurrent Platinum-Resistant Ovarian, Tubal and Peritoneal Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Camptothecin (Primary) ; Bevacizumab
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 28 Sep 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 28 Sep 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 14 Feb 2017 Planned End Date changed from 1 Apr 2016 to 1 Mar 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History